Company Overview
Founded in 2011, by Christopher Micetich and headquartered in Edmonton, Alberta, Fedora Pharmaceuticals Inc. is a biotechnology company dedicated to the discovery and development of novel antimicrobial agents. The company focuses on addressing the critical issue of antimicrobial resistance (AMR), which poses a significant threat to global health.
Mission and Vision
Fedora Pharmaceuticals is dedicated to addressing multi-drug-resistant infections through the development of innovative antibiotics that effectively target resistant pathogens. Our vision is to help shape a future where antibiotic resistance (AMR) is no longer a pressing global health concern.
Major Developments
In 2015, Fedora Pharmaceuticals Inc. received an ASTech Award for Outstanding Commercial Achievement in Alberta Science and Technology. This prestigious award highlights Fedora’s success in developing a new generation of beta-lactamase inhibitors, which at the time in 2014 led to the largest licensing deal in Canadian biotech history with Hoffman La-Roche for up to $750 million plus royalties. The award underscores Fedora’s innovative approach and impactful advancements in combating antimicrobial resistance.
Upcoming Events
Members from our Fedora Pharmaceuticals Inc. team are excited to attend the ESCMID Global conference in Vienna, Austria, from April 11-15, 2025. This premier event in infectious diseases and clinical microbiology will provide an excellent platform for our team to engage with leading experts, explore the latest research, and network with industry peers. By participating in keynote lectures, workshops, and symposia, our team aims to gain valuable insights and forge strategic partnerships that will drive our innovation efforts forward. Fedora looks forward to leveraging this opportunity to enhance our contributions to the field and stay at the forefront of antimicrobial advancements.
Impact and Goals
Fedora Pharmaceuticals boasts a management and scientific team with extensive experience in drug discovery and development. Our collective expertise has led to the creation of numerous anti-infectives currently in clinical use.
In 2023, Christopher Micetich was honoured with induction into the Alberta BioIndustry Hall of Fame. This accolade recognizes his significant contributions to Alberta’s Life Sciences sector, highlighting his impactful work and leadership in the industry over the last +37 years.
Dr. Sameeh Salama, Chief Scientific Officer at Fedora Pharmaceuticals Inc., plays a pivotal role in both national and global initiatives to combat antimicrobial resistance (AMR). Beyond his involvement with the Antimicrobial Resistance Expert Advisory Board on AMR to the Public Health Agency of Canada, Dr. Salama chairs the Canadian Antimicrobial Innovation Coalition (CAIC). In this capacity, he leads efforts to position Canada as a leader in AMR research, product development, and policy advocacy, fostering collaboration among regulators, policymakers, researchers, and industry stakeholders to overcome barriers in AMR innovation.
Fedora Pharmaceuticals is committed to making a significant impact in the fight against AMR and in fact, is presently advancing a promising “first-in-class” candidate compound towards an IND. By developing effective antimicrobial agents, we aim to reduce the global burden of antibiotic-resistant infections and improve patient outcomes.
For more information about Fedora Pharmaceuticals Inc. please visit our website at: www.fedorapharma.com.
